Ligand-selective interdomain conformations of estrogen receptor-alpha

Department of Medicine, University of California, San Francisco, San Francisco, California, United States
Molecular Endocrinology (Impact Factor: 4.02). 02/2007; 21(1):49-61. DOI: 10.1210/me.2006-0075
Source: PubMed


Selective estrogen receptor modulators (SERMs) inhibit estrogen activation of the estrogen receptor (ER) in some tissues but activate ER in other tissues. These tissue-selective actions suggest that SERMs may be identified with tissue specificities that would improve the safety of breast cancer and hormone replacement therapies. The identification of an improved SERM would be aided by understanding the effects of each SERM on the structure and interactions of ER. To date, the inability to obtain structures of the full-length ER has limited our structural characterization of SERM action to their antiestrogenic effects on the isolated ER ligand binding domain. We studied the effects of estradiol and the clinically useful SERMs 4-hydroxytamoxifen and fulvestrant on the conformation of the full-length ERalpha dimer complex by comparing, in living human breast cancer cells, the amounts of energy transfer between fluorophores attached to different domains of ERalpha. Estradiol, 4-hydroxytamoxifen, and fulvestrant all promoted the rapid formation of ERalpha dimers with equivalent interaction kinetics. The amino- and carboxyl-terminal ERalpha domains both contain activation functions differentially affected by these ligands, but the positions of only the carboxyl termini differed upon binding with estradiol, 4-hydroxytamoxifen, or fulvestrant. The association of a specific ERalpha dimer conformation with the binding of ligands of different clinical effect will assist the identification of a SERM with optimal tissue-selective estrogenic and antiestrogenic activities. These studies also provide a roadmap for dissecting important structural and kinetic details for any protein complex from the quantitative analysis of energy transfer.

Download full-text


Available from: Fred Schaufele, Jan 22, 2015
  • Source
    • "In fact other authors have shown nuclear redistribution of different PPAR isoforms by RXR at specific locations [30]. These nuclear foci have also been characterized for other NRs [16], [31] and van Royen et al. (2007) reported that compartmentalization of androgen receptor occurred in foci partly overlapping transcription sites. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nuclear receptors (NR) regulate transcription of genes involved in many biological processes such as development, cell proliferation, differentiation and cell death. Amongst them, PPARG2 and THR control tissue glucose and lipid homeostasis which are deregulated in severe pathophysiological conditions such as metabolic syndromes. Here, we describe a real time BRET approach to monitor heterodimerization between RXR and PPARG2 or THR in vitro or in living cells. The presence of a specific DNA target was required to induce in vitro a BRET shift reflecting heterodimerization of RXR/PPARG2 or RXR/THR. As in electrophoretic mobility shift assay (EMSA), the stringency and specificity of the BRET shift assay depended upon assay condition optimization including MgCl2 concentration. For the nuclear receptors, we found by mutagenesis analysis that each heterodimer partner must harbor an intact DNA binding domain to induce BRET and heterodimerization on a DNA target. Moreover the interaction between the PPARG2 ligand binding domain and the RXR DNA binding domain stabilized the heterodimer on its DNA target. BRET microscopy in living cells highlighted the heterodimerization of RXR/PPARG2 within the nucleus clustered in discrete foci that may represent active target gene transcription regulation regions. BRET imaging also suggested that heterodimerization between RXR and PPARG2 required the DNA binding of PPARG2. The BRET approach described here allowed us to study the dynamic interactions which exist between NR in vitro or in living cells and can provide important information on heterodimerization modes, affinity with a given RE and subcellular localization of the heterodimers. This method could be used to study real time changes of NR heterodimers occurring on DNA depending upon cell activation, chromatin state and help to define the mechanisms of ligands or drug action designed to target NRs.
    Full-text · Article · Dec 2013 · PLoS ONE
  • Source
    • "The precise process of transactivation of genes by ERs is still unresolved. ER can dimerize and bind to its cofactors even when not bound to DNA, which occurs also in the absence of ligands (Carroll et al., 2006; Padron et al., 2007; Zwart et al., 2007a). For proper recruitment of RNA polymerase II, however, the ER needs to be bound to an ERE (Carroll et al., 2006; Sharp et al., 2006; Zwart et al., 2007a). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Human estrogen receptors alpha and beta (ERalpha and ERbeta) greatly differ in their target genes, transcriptional potency and cofactor-binding capacity, and are differentially expressed in various tissues. In classical estrogen response element (ERE)-mediated transactivation, ERbeta has a markedly reduced activation potential compared with ERalpha; the mechanism underlying this difference is unclear. Here, we report that the binding of steroid receptor coactivator-1 (SRC-1) to the AF-1 domain of ERalpha is essential but not sufficient to facilitate synergy between the AF-1 and AF-2 domains, which is required for a full agonistic response to estradiol (E2). Complete synergy is achieved through the distinct hinge domain of ERalpha, which enables combined action of the AF-1 and AF-2 domains. AF-1 of ERbeta lacks the capacity to interact with SRC-1, which prevents hinge-mediated synergy between AF-1 and AF-2, thereby explaining the reduced E2-mediated transactivation of ERbeta. Transactivation of ERbeta by E2 requires only the AF-2 domain. A weak agonistic response to tamoxifen occurs for ERalpha, but not for ERbeta, and depends on AF-1 and the hinge-region domain of ERalpha.
    Preview · Article · Mar 2010 · Journal of Cell Science
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Our long-term goal is to correlate the undesired escape from androgen deprivation therapy with specific molecular events in Androgen Receptor signaling in order to determine the best molecular targets for prostate cancer treatment. Studies supported by this grant indicate that the failure of tumors to respond to anti-androgen therapy corresponded best with an increased nuclear transport of AR. However, an intramolecular fold and AR dimerization, both activated abnormally by heterologous hormones (estrogen and progestin) and measured by fluorescence resonance energy transfer of CFP and YFP-tagged ARs), also was linked to four different AR mutants associated with treatment-refractory prostate proliferation. High throughput methods were developed to measure AR folding, dimerization and nuclear transport. These methods will facilitate the future identification of new drugs that block AR folding, dimerization and nuclear transport and that may prove useful in treatment-refractory therapy.
    Preview · Article · Oct 2007
Show more